OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s Growth
September 07 2016 - 2:00PM
Business Wire
— Christophe Couturier Named Chief Financial
Officer —
— Karen Long Named Executive Vice President,
Clinical and Regulatory Affairs and Quality Assurance —
— James Luterman, Ph.D. Promoted to Executive
Vice President, Research and Development —
OvaScienceSM (NASDAQ: OVAS), a global fertility company focused
on the discovery, development and commercialization of new
treatment options, today announced changes to its senior management
team, reflecting the Company’s continued evolution and global
growth. Christophe Couturier has been named Chief Financial
Officer, effective immediately. He succeeds Jeff Young, who is
pursuing other opportunities and will be leaving OvaScience after a
transition period. Karen Long joins the Company as Executive Vice
President, Clinical and Regulatory Affairs and Quality Assurance
and James Luterman, Ph.D., OvaScience’s Senior Vice President,
Research and Development, has been promoted to Executive Vice
President, Research and Development. All will report directly to
Harald Stock, Ph.D., President and Chief Executive Officer of
OvaScience.
“We welcome Christophe to OvaScience in this critical position
for our path forward. His extensive experience working in a range
of financial roles for global life science companies will be
indispensable as we continue to commercialize our novel treatments
in multiple international markets and will strengthen the already
talented financial team we have in place,” said Harald Stock,
Ph.D., President and Chief Executive Officer of OvaScience. “We
thank Jeff for his numerous contributions to OvaScience and wish
him the best in his future endeavors.”
Christophe Couturier has nearly 20 years of experience with a
proven record in management, finance and strategic planning across
multiple geographies. Most recently, he served as Senior Vice
President and General Manager at Merck KGaA (Darmstadt, Germany),
where he led the Merck KGaA/Pfizer Global Immuno-Oncology Alliance.
Previously, he worked in a series of roles at MilliporeSigma,
including serving as Senior Vice President of the Merck
KGaA/Sigma-Aldrich Integration Program, Vice President of Corporate
Financial Planning and Analysis and Vice President of Finance
Operations for the company’s Bioprocess and BioScience divisions.
Prior to joining Merck KGaA in 2004, Christophe worked as an
Associate Partner at IBM Business Consulting Services, as a Finance
Director at Lloyds Pharmacy and as a Head of Finance for Novartis,
with positions in Hungary, Norway, Turkey and Switzerland. He holds
an M.B.A. from ESSEC Business School in France.
Karen Long joins OvaScience from Danaher, Leica Biosystems,
where she was Vice President, Regulatory Affairs and Quality
Assurance and oversaw the development of the company’s quality
management systems, regulatory, clinical research and compliance
programs. Karen has more than 20 years of industry experience,
including various senior positions in regulatory affairs at Abbott,
Roche Molecular Systems, Inc., Calypte Biomedical Corporation and
Baxter Healthcare Therapeutics. She holds a B.S. in Biochemistry
and Medical Technology from the University of Illinois.
James Luterman, Ph.D. has been with OvaScience since January
2014 and brings over 20 years of industry experience to the
Company. Most recently he served as Senior Vice President, Research
and Development at OvaScience. Prior to OvaScience, Dr. Luterman
held various positions at Shire Human Genetic Therapies. He also
worked at Biogen and Decision Resources Group. He holds a B.A. in
Biology and Psychology from Bucknell University and a Ph.D. in
Behavioral and Neural Sciences from Rutgers University. Dr.
Luterman was a postdoctoral fellow at Mount Sinai School of
Medicine.
Dr. Stock added, “Karen’s background in navigating clinical and
regulatory affairs for international healthcare companies will
provide critical insight as we seek to refine our regulatory
strategies in key international markets. Further, Jim’s scientific
expertise and commitment to building a robust body of preclinical
data have allowed us to ensure the development of our pipeline
treatments – OvaTure and OvaPrime – are on track. I’m eager to work
with Christophe, Karen and Jim on my executive team.”
About OvaScienceOvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for
women around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells – immature
egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in
select international regions. OvaScience has commenced a
non-commercial preceptorship training program with the
OvaPrimeSM treatment, which could increase a woman’s egg
reserve, and is developing the OvaTureSM treatment, a
potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone
injections. OvaScience treatments are not available in the U.S. For
more information, please visit www.ovascience.com and
www.augmenttreatment.com and connect with us on Twitter
and Facebook.
Forward-Looking StatementsThis press release includes
forward-looking statements about the Company’s plans for the
AUGMENT treatment, OvaPrime treatment and OvaTure treatment,
including statements relating to the status of our treatment
programs and contributions by members of the Company’s executive
team. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including risks related to: the possibility that
international IVF clinics that we work with may determine not to
provide or continue providing the AUGMENT treatment or OvaPrime
treatment, or to delay providing such treatments based on clinical
efficacy, safety or commercial, logistic, regulatory or other
reasons; the science underlying our treatments (including the
AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our
ability to obtain regulatory approval or licenses where necessary
for our treatments; our ability to develop our treatments on the
timelines we expect, if at all; our ability to commercialize our
treatments, on the timelines we expect, if at all; as well as those
risks more fully discussed in the “Risk Factors” section of our
most recently filed Quarterly Report on Form 10-Q and/or Annual
Report on Form 10-K. The forward-looking statements contained in
this press release reflect our current views with respect to future
events. We anticipate that subsequent events and developments will
cause our views to change. However, while we may elect to update
these forward-looking statements in the future, we specifically
disclaim any obligation to do so. These forward-looking statements
should not be relied upon as representing our view as of any date
subsequent to the date hereof.
###
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906006504/en/
Media and Investor Contact:OvaScienceJennifer
Viera, 617-420-8748jviera@ovascience.com
Ovascience Inc. (delisted) (NASDAQ:OVAS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovascience Inc. (delisted) (NASDAQ:OVAS)
Historical Stock Chart
From Apr 2023 to Apr 2024